OUR SERVICES: Intraday Trading Calls, Future & Option Tips, Commodity Market Tips,Positional Option Tips, Stock Tips, Commodity Tips, Ncdex Tips
·
RBI revises norms for
Borrowing Entities outside SDR
RBI has decided to
allow banks to upgrade the credit facilities extended to borrowing entities
whose ownership has been changed outside SDR (strategic debt restructuring), to
‘Standard’ category upon such change in ownership, subject to certain
conditions (eg the change in ownership is by way of sale by lenders to new
promoters, the new promoters must have 51% stake and should not have any
relation with exiting company etc).
·
Dr Reddy's surges on launch of
Esomeprazole Magnesium
Shares of Dr
Reddy’s Laboratories rallied 6% to Rs4222 on the NSE in an otherwise subdued
market after the drug maker announced the launch of Esomeprazole Magnesium
Delayed-release capsules, which is the generic version of AstraZeneca's
Nexium®, in the US market.
·
Government’s holding in IDBI
Bank to be reduced to 49%
Government’s
holding in IDBI Bank to be reduced to 49% -- sentimentally positive for IDBI
bank. As per media reports, the government has firmed up plans to bring down
its holding in IDBI Bank 49%, marking a big bang start to its commitment to
reform state-run banks.
·
IndusInd Bank grants options to
new Joinees
IndusInd Bank Ltd
has informed BSE that the Bank has, on September 21, 2015, granted 193,000
Options to 8 new joinees, as a part of pre-hiring negotiations. The Grant
of Options is on the basis of receipt of necessary approvals, in accordance
with the Securities and Exchange Board of India (Share Based Employee Benefits)
Regulations, 2014 and the ESOP Scheme 2007 of the Bank.
·
SPARC, Sun Pharma drop as USFDA
cancels Seizure drug over compliance issues
FDA cancels
Sun Pharma Advance Research Company Ltd’s (SPARC) Seizure drug over
compliance issues – Negative for Sun Pharma and SPARC. Shares of
Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company
(SPARC) fell 3% each after the US Food and Drugs Administration ( USFDA)
withdrew an approval granted in March to SPARC’s anti-epileptic drug due to
regulatory compliance issues at Sun Pharma's Halol plant.
·
Col-Pal increases paid-up
capital to Rs27,19,85,634
Colgate Palmolive (India) Outcome
of Stakeholders’ Relationship Committee Meeting - Increase in the paid-up
Capital of the Company on account of Bonus Issue. Colgate Palmolive (India) Ltd
has informed BSE that on July 30, 2015, the Board of Directors of the Company
approved the Issue of Bonus Equity Shares. On September 11, 2015, the
shareholders, through the Postal Ballot approved the resolution of issue of
bonus shares in the ratio of 1:1 to the eligible shareholders of the Company.
